Judge Rejected Pfizer and Moderna Patent Dismissals
A federal court ruled that patent lawsuits regarding mRNA technology against major vaccine makers will proceed.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Do patent lawsuits against vaccine manufacturers decrease your trust in pharmaceutical companies?
A federal judge in Delaware has rejected requests by Pfizer, BioNTech, and Moderna to dismiss patent infringement lawsuits. The cases, initiated by Bayer's Monsanto unit, center on the messenger RNA technology used in COVID-19 vaccines.
Why it matters
The ruling allows patent litigation over mRNA technology to move forward in the U.S. court system, potentially shaping the intellectual property landscape for future vaccine development.
The litigation involves case numbers 1:26-cv-00012 for the suit against Moderna and 1:26-cv-00013 for the suit against Pfizer. These legal challenges target the proprietary messenger RNA technology foundational to the COVID-19 vaccines developed by the companies.
The players
Bayer
A global life sciences company that operates the Monsanto unit involved in this mRNA patent litigation.
Pfizer
A pharmaceutical manufacturer that developed a COVID-19 vaccine utilizing mRNA technology.
Moderna
A biotechnology company focused on mRNA therapeutics and developer of a COVID-19 vaccine.
The details
The US District Court for the District of Delaware denied motions to dismiss filed by the vaccine manufacturers, clearing a path for the litigation to continue. The dispute centers on mRNA technology—a method of using genetic material to instruct cells to produce proteins—that serves as the basis for the specific COVID-19 vaccines in question.
Timeline
September 28, 2026: A federal judge rejected dismissal requests from Pfizer, BioNTech, and Moderna.
The Tech Race
The litigation follows a pattern set by previous high-profile intellectual property disputes concerning core vaccine platform technologies. These cases represent the latest effort by industrial giants to assert control over the foundational mRNA architecture now central to the global biotech pipeline.
The continuation of these lawsuits will not affect the current availability of vaccines, as this is a legal dispute between large corporations regarding intellectual property. Stakeholders should monitor the court docket for trial scheduling and discovery updates.
The takeaway
This ruling ensures the legal battle over messenger RNA property rights will proceed to further stages in the Delaware district court. Observers should track the upcoming proceedings in case numbers 1:26-cv-00012 and 1:26-cv-00013 for future developments in the case timeline.
Further reading
For broader context on current intellectual property developments in the field, see the Biotech section.
Source note: This article includes information reported by Reuters.
Live Poll
Do patent lawsuits against vaccine manufacturers decrease your trust in pharmaceutical companies?
